Literature DB >> 24938904

Microwave ablation (MWA) for the treatment of a solitary, chemorefractory testicular cancer liver metastasis.

Elena G Violari1, Elena N Petre, Darren R Feldman, Joseph P Erinjeri, Karen T Brown, Stephen B Solomon, Michael I D'Angelica, Constantinos T Sofocleous.   

Abstract

We present a case of a patient with stage IIIC metastatic seminoma with a persistent chemorefractory liver lesion. The patient was deemed a poor surgical candidate due to the tumor's aggressive biology with numerous other liver lesions treated with chemotherapy and a relatively high probability for additional recurrences. Further chemotherapy with curative intent was not a feasible option due to the fact that the patient had already received second-line high-dose chemotherapy and four cycles of third-line treatment complicated by renal failure, refractory thrombocytopenia, and debilitating neuropathy. After initial failure of laser, microwave ablation of the chemorefractory liver metastasis resulted in prolonged local tumor control and rendered the patient disease-free for more than 35 months, allowing him to regain an improved quality of life.

Entities:  

Mesh:

Year:  2014        PMID: 24938904      PMCID: PMC9375177          DOI: 10.1007/s00270-014-0924-z

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.797


  26 in total

1.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. 1997.

Authors:  Lawrence H Einhorn; John Donohue
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

2.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

3.  Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).

Authors:  William G Jones; Sophie D Fossa; Graham M Mead; J Trevor Roberts; Michael Sokal; Alan Horwich; Sally P Stenning
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

4.  Superselective internal radiation with yttrium-90 microspheres in the management of a chemorefractory testicular liver metastasis.

Authors:  Panagiotis A Sideras; Constantinos T Sofocleous; Lynn A Brody; Robert H Siegelbaum; Rajesh P Shah; Neeta-Pandit Taskar
Journal:  Cardiovasc Intervent Radiol       Date:  2011-07-20       Impact factor: 2.740

5.  Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up.

Authors:  Luigi Solbiati; Muneeb Ahmed; Luca Cova; Tiziana Ierace; Michela Brioschi; S Nahum Goldberg
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

Review 6.  Medical treatment of advanced testicular cancer.

Authors:  Darren R Feldman; George J Bosl; Joel Sheinfeld; Robert J Motzer
Journal:  JAMA       Date:  2008-02-13       Impact factor: 56.272

7.  Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

Authors:  Ashraf A Mosharafa; Richard S Foster; Bradley C Leibovich; Richard Bihrle; Cynthia Johnson; John P Donohue
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

8.  Particle embolization for hepatocellular carcinoma.

Authors:  K T Brown; A B Nevins; G I Getrajdman; L A Brody; R C Kurtz; Y Fong; L H Blumgart
Journal:  J Vasc Interv Radiol       Date:  1998 Sep-Oct       Impact factor: 3.464

9.  Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Diane Reidy-Lagunes; Ivan K Ip; William Alago; Anne M Covey; Joseph P Erinjeri; Lynn A Brody; Majid Maybody; Raymond H Thornton; Stephen B Solomon; George I Getrajdman; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2014-01       Impact factor: 3.682

10.  Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

Authors:  R de Wit; G Stoter; D T Sleijfer; S B Kaye; P H de Mulder; W W ten Bokkel Huinink; P J Spaander; M de Pauw; R Sylvester
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.